Bortezomib in the management of multiple myeloma

by Jacob P Laubach, Constantine S Mitsiades, Teru Hideshima, et al
Published 2009-09-01

Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma

by Jacob P. Laubach, Sascha A. Tuchman, Jacalyn M. Rosenblatt, Constantine S. Mitsiades, Kathleen Colson, Kelly Masone, Diane Warren, Robert A. Redd, Dena Grayson, Paul G. Richardson
Published 2021-02-01

Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translation.

by Douglas W McMillin, Jake Delmore, Joseph Negri, Melissa Ooi, Steffen Klippel, Chandrasekhar V Miduturu, Nathanael S Gray, Paul G Richardson, Kenneth C Anderson, Andrew L Kung, Constantine S Mitsiades
Published 2011-01-01

A genome-wide Drosophila epithelial tumorigenesis screen identifies Tetraspanin 29Fb as an evolutionarily conserved suppressor of Ras-driven cancer.

by Tamara Zoranovic, Jan Manent, Lee Willoughby, Ricardo Matos de Simoes, John E La Marca, Sofya Golenkina, Xia Cuiping, Susanne Gruber, Belinda Angjeli, Elisabeth Eva Kanitz, Shane J F Cronin, G Gregory Neely, G Gregory Neely, Andreas Wernitznig, Patrick O Humbert, Kaylene J Simpson, Constantine S Mitsiades, Helena E Richardson, Josef M Penninger
Published 2018-10-01